IPO registrations (S-1, F-1) · Registrants

LUMOS PHARMA, INC.

SEC CIK
1126234 · filings on EDGAR ↗
Name on the registration
NEWLINK GENETICS CORP
Former names
NEWLINK GENETICS CORP (2002–2020)
Registration
Form S-1, first filed 2010-12-21, last 2011-11-10; 1 initial registration, 7 amendments
Outcome
Final prospectus filed 2011-11-14; declared effective 2011-11-10
Industry (SIC)
Pharmaceutical Preparations 2834
Incorporated in
DE
Business address
4200 MARATHON BLVD., SUITE 200, Austin, TX 78756
EIN
42-1491350
EDGAR entity type
operating
Insiders and CEO pay
LUMOS PHARMA, INC. on the corporate pages

Offering terms

Final price
$7.00 per share (424B4 filed 2011-11-14, an initial public offering)
Shares sold
6,200,000
Gross proceeds
$43,400,000 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol NLNK
Lead underwriters
Stifel (2,867,500 shares); Canaccord Genuity (1,937,500 shares); Baird (930,000 shares); Cantor Fitzgerald (465,000 shares)

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 11

FiledFormWhat it isName as filedEDGAR
2010-12-21S-1S-1 (registration)NEWLINK GENETICS CORP0001047469-10-010516 ↗
2011-02-28S-1/AS-1/A (amendment)NEWLINK GENETICS CORP0001047469-11-001496 ↗
2011-03-18S-1/AS-1/A (amendment)NEWLINK GENETICS CORP0001047469-11-002351 ↗
2011-09-14S-1/AS-1/A (amendment)NEWLINK GENETICS CORP0001047469-11-008009 ↗
2011-10-04S-1/AS-1/A (amendment)NEWLINK GENETICS CORP0001047469-11-008354 ↗
2011-10-26S-1/AS-1/A (amendment)NEWLINK GENETICS CORP0001047469-11-008688 ↗
2011-11-08S-1/AS-1/A (amendment)NEWLINK GENETICS CORP0001047469-11-009169 ↗
2011-11-10S-1/AS-1/A (amendment)NEWLINK GENETICS CORP0001047469-11-009373 ↗
2011-11-10EFFECTEFFECT (declared effective)NEWLINK GENETICS CORP9999999995-11-003221 ↗
2011-11-14424B4424B4 (final prospectus)NEWLINK GENETICS CORP0001047469-11-009408 ↗
2013-01-04EFFECTEFFECT (declared effective)NEWLINK GENETICS CORP9999999995-13-000131 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2011-11-10S-1/Aregistration statement$5.00--0primary document; price linedocument ↗
2011-11-14424B4final prospectus$7.006,200,000$43,400,000Nasdaq NLNK4primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 4document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
Alexander SarahDirector22011
Edick Paul RDirector122011–2017
Link Charles J. Jr.Director,Officer; Director,Officer,TenPercentOwnerChairman of the Board and CEO; Chairman of the Board & CEO592011–2019
LINK GORDON H JROfficerChief Financial Officer182011–2014
Lundquist David J.Director52011–2012
Lynn KennethOfficer; OtherExec VP of Bus Developement; Exec VP of Bus Development42011–2012
Raffin Thomas A.Director232011–2024
Ramsey William J.OfficerQuality Assurance Officer272011–2015
Saluri JosephDirector142011–2017
Stine Seed Farm, Inc.TenPercentOwner42011–2017
Talarico Ernest IIIDirector212011–2019
Vahanian Nicholas N.OfficerPres and Chief Medical Officer; Pres, Chief Medical Officer; President; President, Chief Medical Offic; President Chief Medical Office312011–2019
Zoth Lota S.Director192012–2024
Wiley BrianOfficerChief Commercial Officer; VP of Business Development172013–2018
Langren Carl W.OfficerChief Financial Officer; Principal Accounting Officer272013–2021
HENNEMAN JOHN B IIIOfficerChief Administrative Officer; EVP, Chief Financial Officer162014–2018
Pucci PaoloDirector42015–2018
Kennedy Eugene P.OfficerChief Medical Officer142017–2021
JOHNSON CHAD ALLENDirector102018–2024
Sherman Matthew LDirector42018–2019
Lawley Lori DOfficerChief Financial Officer; Principal Accounting Officer182018–2024
POWERS BRADLEY JOfficerGeneral Counsel; Principal Executive Officer122019–2024
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)TenPercentOwnerOther22020–2021
Deerfield Mgmt III, L.P.TenPercentOwnerOther22020–2021
Deerfield Private Design Fund III, L.P.TenPercentOwnerOther22020–2021
Flynn James ETenPercentOwnerOther22020–2021person page Fuzzy
Cunningham EmmettDirector22020
Hawkins Richard JDirector,OfficerChief Executive Officer132020–2024
LALANDE KEVIN M.Director142020–2024
McCracken Joseph SDirector102020–2024
McKew John C.OfficerChief Scientific Officer192020–2024
van Es-Johansson AnDirector62021–2024
Schuchart AaronOfficerChief Business Officer82021–2024
Karpf David BOfficerChief Medical Officer42021–2023
Pitukcheewanont Pisit DukeOfficerChief Medical Officer52024

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationNEWLINK GENETICS CORPORATIONState business registriesEIN (EXACT, as the state registration reports it)
Form 5500 plan sponsorLUMOS PHARMA, INC.EIN (EXACT)
Form D issuerLumos Pharma, Inc.Form D private offeringsname and state
Person pageJames E FlynnPeople (Form 990 officers, directors and employees)officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwnerOther)
SEC filerLUMOS PHARMA, INC.SEC filers (EDGAR)CIK (EXACT)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.